drugset / Trial / NCT04720183

Drug-drug Interaction Study with GLPG3970 and Sulfasalazine in Adult, Healthy Subjects

NCT04720183

Phase 1 Completed 8 enrolled Lakefront Biotherapeutics NV
NaSequentialOpen-labelBasic science

Summary

GLPG3970 will be given with sulfasalazine to investigate the effect of co-administration on the pharmacokinetics of sulfasalazine, and on the safety and tolerability of the drugs in healthy adult subjects.

Timeline

Start
2021-01-11
Primary completion
2021-04-21
Completion
2021-04-23

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG3970 Unknown Oral
Subject Sulfasalazine Small molecule Oral

Indications

No indication recorded.